

# Acute Migraine Therapy: Do Doctors Understand What Therapy?

Headache

39, S20-S26

DOI: [10.1111/j.1526-4610.1999.00006.x](https://doi.org/10.1111/j.1526-4610.1999.00006.x)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Eletriptan for acute migraine. , 2000, , CD003224.		6
2	Within-patient consistency of response of rizatriptan for treating migraine. <i>Neurology</i> , 2000, 55, 1511-1516.	1.5	41
3	Determinants of Patient Satisfaction With Migraine Therapy. <i>Cephalalgia</i> , 2000, 20, 554-560.	1.8	149
4	Guidelines for Controlled Trials of Drugs in Migraine: Second Edition. <i>Cephalalgia</i> , 2000, 20, 765-786.	1.8	615
5	Acute Migraine Treatment Outcome Measures: A Clinician's View. <i>Cephalalgia</i> , 2000, 20, 14-24.	1.8	40
6	Rizatriptan: A New Milestone in Migraine Treatment. Introduction. <i>Cephalalgia</i> , 2000, 20, 1-1.	1.8	5
7	Rizatriptan in Acute Treatment of Migraine: Update on New Comparative Data. <i>Cephalalgia</i> , 2000, 20, 10-15.	1.8	18
8	Treatment of Mild Headache in Disabled Migraine Sufferers: Results of the Spectrum Study. <i>Headache</i> , 2000, 40, 792-797.	1.8	169
9	Cost-Benefit Analysis of Sumatriptan Tablets versus Usual Therapy for Treatment of Migraine. <i>Pharmacotherapy</i> , 2000, 20, 1356-1364.	1.2	17
10	Rizatriptan for acute migraine. , 2000, , CD003221.		9
11	Effect of early intervention with sumatriptan on migraine pain: Retrospective analyses of data from three clinical trials. <i>Clinical Therapeutics</i> , 2000, 22, 1035-1048.	1.1	217
12	The Role of the Patient in Maximizing Efficacy of Drug Therapy in Migraine. <i>Disease Management and Health Outcomes</i> , 2001, 9, 187-201.	0.3	2
13	Comparative aspects of triptans in treating migraine. <i>Clinical Cornerstone</i> , 2001, 4, 53-64.	1.0	12
14	Economic implications of early treatment of migraine with sumatriptan tablets. <i>Clinical Therapeutics</i> , 2001, 23, 284-291.	1.1	25
15	Current options for the prevention and treatment of migraine. <i>Clinical Therapeutics</i> , 2001, 23, 772-788.	1.1	42
16	Oral triptans (serotonin 5-HT 1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. <i>Lancet</i> , The, 2001, 358, 1668-1675.	6.3	927
17	When Should Triptans be Taken During a Migraine Attack?. <i>CNS Drugs</i> , 2001, 15, 583-587.	2.7	24
18	Patient Treatment Preferences and the 5-HT1B/1D Agonists. <i>Archives of Internal Medicine</i> , 2001, 161, 2545.	4.3	19

#	ARTICLE	IF	CITATIONS
19	Eletriptan for acute migraine. The Cochrane Library, 2001, , CD003224.	1.5	11
20	Rizatriptan for acute migraine. The Cochrane Library, 2001, , CD003221.	1.5	6
21	Preference Comparison of Rizatriptan ODT 10-mg and Sumatriptan 50-mg Tablet in Migraine. Headache, 2001, 41, 745-753.	1.8	48
22	An Open Preference Study with Sumatriptan 50 mg and Zolmitriptan 2.5 mg in 100 Migraine Patients. Cephalalgia, 2001, 21, 680-684.	1.8	27
23	Acute and prophylactic management of migraine. Clinical Cornerstone, 2001, 4, 36-52.	1.0	24
24	Establishing a Standard of Speed for Assessing the Efficacy of the Serotonin1B/1D Agonists (Triptans). Archives of Neurology, 2001, 58, 1056.	4.9	15
25	Integrating the triptans into clinical practice. Current Opinion in Neurology, 2002, 15, 317-322.	1.8	42
26	Communicating the Right Therapy for the Right Patient at the Right Time: Acute Therapy. Canadian Journal of Neurological Sciences, 2002, 29, S33-S39.	0.3	5
27	Migraine " Current Understanding and Treatment. New England Journal of Medicine, 2002, 346, 257-270.	13.9	1,692
28	Almotriptan. Drugs, 2002, 62, 387-414.	4.9	21
29	Diagnosis and Treatment of Migraine. Mayo Clinic Proceedings, 2002, 77, 255-261.	1.4	100
30	Global Trends in Migraine Care. CNS Drugs, 2002, 16, 13-18.	2.7	62
31	Patient Perceptions and Treatment Preferences in Migraine Management. CNS Drugs, 2002, 16, 19-24.	2.7	16
32	Practical Approaches to Migraine Management. CNS Drugs, 2002, 16, 385-403.	2.7	10
33	Use of rescue medication in trials of almotriptan versus placebo in the treatment of acute migraine. Clinical Therapeutics, 2002, 24, 520-529.	1.1	6
34	Pharmacological treatments for acute migraine: quantitative systematic review. Pain, 2002, 97, 247-257.	2.0	126
35	Do Butalbital-Containing Products Have a Role in the Management of Migraine?. Pharmacotherapy, 2002, 22, 1029-1035.	1.2	31
36	Initial abortive treatments for migraine headache. Current Treatment Options in Neurology, 2002, 4, 343-350.	0.7	7

#	ARTICLE	IF	CITATIONS
37	Triptans: Are they all the same?. Current Pain and Headache Reports, 2002, 6, 140-146.	1.3	3
38	Validation of the Patient Perception of Migraine Questionnaire. Value in Health, 2002, 5, 422-430.	0.1	25
39	Almotriptan Increases Sustained Pain-Free Outcomes in Acute Migraine: Results From Three Controlled Clinical Trials. Headache, 2002, 42, 21-27.	1.8	19
40	Migraine, Midrin, and Imitrex. Headache, 2002, 42, 322-323.	1.8	2
41	Research into Headache: The Contribution of Qualitative Methods. Headache, 2002, 42, 1051-1059.	1.8	23
42	What Do Patients With Migraine Want From Acute Migraine Treatment?. Headache, 2002, 42, 3-9.	1.8	214
43	Tripstar: A Comprehensive Patient-Based Approach to Compare Triptans. Headache, 2002, 42, 18-25.	1.8	8
44	Almotriptan Reduces the Incidence of Migraine-Associated Symptoms: A Pooled Analysis. Headache, 2002, 42, 26-31.	1.8	5
45	Almotriptan Increases Pain-Free Status in Patients With Acute Migraine Treated in Placebo-Controlled Clinical Trials. Headache, 2002, 42, 32-37.	1.8	31
46	Finasteride in the treatment of clinical benign prostatic hyperplasia: A systematic review of randomised trials. BMC Urology, 2002, 2, 14.	0.6	62
47	Rizatriptan Combined with Rofecoxib Vs. Rizatriptan for the Acute Treatment of Migraine: an Open Label Pilot Study. Cephalalgia, 2002, 22, 309-312.	1.8	57
48	Triptans (Serotonin, 5-HT <sub>1B/1D</sub> Agonists) in Migraine: Detailed Results and Methods of A Meta-Analysis of 53 Trials. Cephalalgia, 2002, 22, 633-658.	1.8	554
49	Determinants of Migraine-Specific Quality of Life. Cephalalgia, 2002, 22, 680-685.	1.8	39
50	A Cost-Effectiveness Analysis of Eletriptan 40 and 80 mg versus Sumatriptan 50 and 100 mg in the Acute Treatment of Migraine. Value in Health, 2003, 6, 438-447.	0.1	20
51	Migraine Prevalence and Treatment Patterns: The Global Migraine and Zolmitriptan Evaluation Survey. Headache, 2003, 43, 19-26.	1.8	184
52	Migraine Medication Attributes Important for Patient Compliance: Concerns About Side Effects May Delay Treatment. Headache, 2003, 43, 36-43.	1.8	161
53	Single Use of Sumatriptan: A Patient Interview Study. Headache, 2003, 43, 109-116.	1.8	23
54	Real-World Experiences in Migraine Therapy With Rizatriptan. Headache, 2003, 43, 223-230.	1.8	10

#	ARTICLE	IF	CITATIONS
55	Efficacy of a Fixed Combination of Indomethacin, Prochlorperazine, and Caffeine Versus Sumatriptan in Acute Treatment of Multiple Migraine Attacks: A Multicenter, Randomized, Crossover Trial. <i>Headache</i> , 2003, 43, 835-844.	1.8	39
56	Early Intervention With Almotriptan Improves Sustained Pain-free Response in Acute Migraine. <i>Headache</i> , 2003, 43, 1075-1079.	1.8	68
57	Migraine Prophylactic Medication Usage Patterns in the Netherlands. <i>Cephalalgia</i> , 2003, 23, 293-301.	1.8	34
58	Patients' Decision-Making for Migraine and Chronic Daily Headache Management. A Qualitative Study. <i>Cephalalgia</i> , 2003, 23, 833-841.	1.8	46
59	Comparative Efficacy of Eletriptan vs. Naratriptan in the Acute Treatment of Migraine. <i>Cephalalgia</i> , 2003, 23, 869-876.	1.8	50
60	Comparative Efficacy of Eletriptan and Zolmitriptan in the Acute Treatment of Migraine. <i>Cephalalgia</i> , 2003, 23, 942-952.	1.8	75
61	Pain-Free Results With Sumatriptan Taken at the First Sign of Migraine Pain: 2 Randomized, Double-Blind, Placebo-Controlled Studies. <i>Mayo Clinic Proceedings</i> , 2003, 78, 1214-1222.	1.4	80
62	Newer Formulations of the Triptans. <i>Drugs</i> , 2003, 63, 2285-2305.	4.9	31
63	Pain-free efficacy after treatment with sumatriptan in the mild pain phase of menstrually associated migraine. <i>Obstetrics and Gynecology</i> , 2003, 102, 835-842.	1.2	63
64	A review of the effects of almotriptan and other triptans on clinical trial outcomes that are meaningful to patients with migraine. <i>Clinical Therapeutics</i> , 2003, 25, 331-341.	1.1	14
65	Migraine treatment patterns and patient satisfaction with prior therapy: A substudy of a multicenter trial of rizatriptan effectiveness. <i>Clinical Therapeutics</i> , 2003, 25, 2053-2069.	1.1	19
66	Cost-effectiveness of almotriptan and rizatriptan in the treatment of acute migraine. <i>Clinical Therapeutics</i> , 2003, 25, 2903-2919.	1.1	21
67	An open-label study to assess changes in efficacy and satisfaction with migraine care when patients have access to multiple sumatriptan succinate formulations. <i>Clinical Therapeutics</i> , 2003, 25, 235-246.	1.1	13
68	Tolerability and Consistency of Effect of Zolmitriptan Nasal Spray in a Long-Term Migraine Treatment Trial. <i>CNS Drugs</i> , 2003, 17, 839-851.	2.7	30
69	Disease Management of Migraine and the Importance of Stratified Care. <i>Disease Management and Health Outcomes</i> , 2003, 11, 379-388.	0.3	1
70	Speed of Onset and Efficacy of Zolmitriptan Nasal Spray in the Acute Treatment of Migraine. <i>CNS Drugs</i> , 2003, 17, 653-667.	2.7	99
71	Pain-Free Efficacy After Treatment With Sumatriptan in the Mild Pain Phase of Menstrually Associated Migraine. <i>Obstetrics and Gynecology</i> , 2003, 102, 835-842.	1.2	38
72	Oral sumatriptan for acute migraine. , 2003, , CD002915.		40

#	ARTICLE	IF	CITATIONS
73	Patterns of health care utilization for migraine in England and in the United States. <i>Neurology</i> , 2003, 60, 441-448.	1.5	159
74	Tips for managing chronic pain. <i>Postgraduate Medicine</i> , 2003, 113, 49-98.	0.9	7
75	A new nasal spray treatment for migraine. <i>Practice Nursing</i> , 2003, 14, 136-138.	0.1	0
76	Analyses of Cost-Effectiveness of Migraine Therapies Should Consider Multiple Measures. <i>Journal of Managed Care Pharmacy</i> , 2003, 9, 279-281.	2.2	1
77	A Comparison of the Cost-Effectiveness of Almotriptan and Sumatriptan in the Treatment of Acute Migraine Using a Composite Efficacy/Tolerability End Point. <i>Journal of Managed Care Pharmacy</i> , 2004, 10, 259-265.	2.2	21
78	Migraine treatment strategies: the global Migraine And Zolmitriptan Evaluation (MAZE) survey â€“ phase IV”. <i>Current Medical Research and Opinion</i> , 2004, 20, 1777-1783.	0.9	11
79	Pharmacokinetic profile of a new form of sumatriptan tablets in healthy volunteers. <i>Current Medical Research and Opinion</i> , 2004, 20, 803-809.	0.9	27
80	The therapeutic profile of zolmitriptan in clinical practice. <i>International Journal of Clinical Practice</i> , 2004, 58, 795-800.	0.8	1
81	Efficacy and tolerability of sumatriptan tablets administered during the mild-pain phase of menstrually associated migraine. <i>International Journal of Clinical Practice</i> , 2004, 58, 913-919.	0.8	57
82	Acute Migraine: Which Triptan?. <i>Practical Neurology</i> , 2004, 4, 6-19.	0.5	11
83	Double-Blind Clinical Trials of Oral Triptans Vs Other Classes of Acute Migraine Medication â€” A Review. <i>Cephalalgia</i> , 2004, 24, 321-332.	1.8	71
84	Patient Preference in Clinical Trials for Headache Medication: The Patient's View. <i>Cephalalgia</i> , 2004, 24, 347-355.	1.8	13
85	Attitudes and Burden of disease among Self-Considered Migraineurs â€” a Nation-wide Population-based Survey in Sweden. <i>Cephalalgia</i> , 2004, 24, 455-465.	1.8	99
86	Early Treatment of a Migraine Attack while Pain is Still Mild Increases the Efficacy of Sumatriptan. <i>Cephalalgia</i> , 2004, 24, 925-933.	1.8	71
87	What Do Patients Want from Acute Migraine Treatment?. <i>Cephalalgia</i> , 2004, 24, 8-15.	1.8	189
88	Clinical Profile and Practice Experience of Almotriptan. <i>Cephalalgia</i> , 2004, 24, 16-23.	1.8	17
89	Clinical Benefits of Early Triptan Therapy for Migraine. <i>Cephalalgia</i> , 2004, 24, 24-30.	1.8	210
90	Morbidity and Medication Preferences of Individuals With Headache Presenting to a Community Pharmacy. <i>Headache</i> , 2004, 44, 90-94.	1.8	15

#	ARTICLE	IF	CITATIONS
91	Onset of Effect of 5-HT <sub>1B/1D</sub> Agonists: A Model With Pharmacokinetic Validation. <i>Headache</i> , 2004, 44, 142-147.	1.8	39
92	Almotriptan Improves Response Rates When Treatment Is Within 1 Hour of Migraine Onset. <i>Headache</i> , 2004, 44, 318-322.	1.8	60
93	Consensus Statement: Cardiovascular Safety Profile of Triptans (5-HT <sub>1B/1D</sub> Agonists) in the Acute Treatment of Migraine. <i>Headache</i> , 2004, 44, 414-425.	1.8	327
94	Rizatriptan versus rizatriptan plus rofecoxib versus rizatriptan plus tolfenamic acid in the acute treatment of migraine. <i>BMC Neurology</i> , 2004, 4, 10.	0.8	39
95	Treatment preferences and the selection of acute migraine medications: results from a population-based survey. <i>Journal of Headache and Pain</i> , 2004, 5, 123-130.	2.5	14
96	Zolmitriptan nasal spray provides fast relief of migraine symptoms and is preferred by patients: a Swedish study of preference in clinical practice. <i>Journal of Headache and Pain</i> , 2004, 5, 237-242.	2.5	12
97	Prioritizing treatment attributes and their impact on selecting an oral triptan: Results from the TRIPSTAR project. <i>Current Pain and Headache Reports</i> , 2004, 8, 435-442.	1.3	15
98	Naratriptan for the treatment of acute migraine: meta-analysis of randomised controlled trials. <i>Pharmacoepidemiology and Drug Safety</i> , 2004, 13, 73-82.	0.9	36
99	Acute Treatment of Migraine with Zolmitriptan 5mg Orally Disintegrating Tablet. <i>CNS Drugs</i> , 2004, 18, 1133-1141.	2.7	27
100	Non-Oral Delivery Systems in Headache Therapy. <i>American Journal of Drug Delivery</i> , 2004, 2, 59-68.	0.6	4
101	Challenging or difficult headache patients. <i>Primary Care - Clinics in Office Practice</i> , 2004, 31, 429-440.	0.7	6
102	Early migraine intervention with sumatriptan 100 mg in patients with a history of nonresponse to sumatriptan 50 mg: an open-label, prospective study of multiple attacks. <i>Current Therapeutic Research</i> , 2004, 65, 353-359.	0.5	1
103	Efficacy and tolerability of sumatriptan tablets in a fast-disintegrating, rapid-release formulation for the acute treatment of migraine: Results of a multicenter, randomized, placebo-controlled study. <i>Clinical Therapeutics</i> , 2004, 26, 214-223.	1.1	73
104	Optimize Migraine Management in Primary Care. <i>Nurse Practitioner</i> , 2004, 29, 22-31.	0.2	3
105	Patient Satisfaction with Migraine Management by Family Physicians. <i>Journal of the American Board of Family Medicine</i> , 2005, 18, 563-566.	0.8	16
106	Parenteral Dihydroergotamine for Acute Migraine Headache: A Systematic Review of the Literature. <i>Annals of Emergency Medicine</i> , 2005, 45, 393-401.	0.3	44
107	Multiple attack study on the available triptans in Italy versus placebo. <i>European Journal of Neurology</i> , 2005, 12, 557-563.	1.7	11
108	Efficacy of oral naratriptan in the treatment of menstrually related migraine. <i>European Journal of Neurology</i> , 2005, 12, 774-781.	1.7	64

#	ARTICLE	IF	CITATIONS
109	An Assessment of the Burden of Migraine using the Willingness to Pay Model. <i>Cephalalgia</i> , 2005, 25, 87-100.	1.8	31
110	Assessment of Migraineurs Referred to a Specialist Headache Clinic in Singapore: Diagnosis, Treatment Strategies, Outcomes, Knowledge of Migraine Treatments And Satisfaction. <i>Cephalalgia</i> , 2005, 25, 1122-1132.	1.8	14
111	Rizatriptan 10-mg Wafer Versus Usual Nontriptan Therapy for Migraine: Analysis of Return to Function and Patient Preference. <i>Headache</i> , 2005, 45, 1140-1150.	1.8	14
112	Patterns and Predictors of Prescription Medication Use in the Management of Headache: Findings From the 2000 Medical Expenditure Panel Survey. <i>Headache</i> , 2005, 45, 1171-1180.	1.8	23
113	Triptan Nonresponder Studies: Implications for Clinical Practice. <i>Headache</i> , 2005, 45, 156-162.	1.8	116
114	Pilot Study Evaluating Preference for 3mg Versus 6mg Subcutaneous Sumatriptan. <i>Headache</i> , 2005, 45, 346-349.	1.8	17
115	Patients' Management of Migraine and Chronic Daily Headache: A Study of the Members of the Migraine Action Association (United Kingdom). <i>Headache</i> , 2005, 45, 571-581.	1.8	14
116	Consistent Efficacy, Tolerability, and High Levels of Satisfaction With Almotriptan 12.5 mg When Used to Treat Multiple Migraine Attacks in Routine Clinical Practice. <i>Headache</i> , 2005, 45, 624-631.	1.8	10
117	An Economic Evaluation of Triptan Products for Migraine. <i>Value in Health</i> , 2005, 8, 647-655.	0.1	17
118	Focus on trial endpoints of clinical relevance and the use of almotriptan for the acute treatment of migraine. <i>International Journal of Clinical Practice</i> , 2005, 59, 1356-1365.	0.8	12
119	The use of multiattribute decision models in evaluating triptan treatment options in migraine. <i>Journal of Neurology</i> , 2005, 252, 1026-1032.	1.8	22
120	The patients' perceptions of migraine and chronic daily headache: a qualitative study. <i>Journal of Headache and Pain</i> , 2005, 6, 40-47.	2.5	39
121	Non-oral formulations of triptans and their use in acute migraine. <i>Current Pain and Headache Reports</i> , 2005, 9, 206-212.	1.3	20
122	How treatment priorities influence triptan preferences in clinical practice: perspectives of migraine sufferers, neurologists, and primary care physicians. <i>Current Medical Research and Opinion</i> , 2005, 21, 413-424.	0.9	32
123	Eletriptan in migraine. <i>Expert Review of Neurotherapeutics</i> , 2005, 5, 43-53.	1.4	13
124	Defining Response in Migraine: Which Endpoints Are Important?. <i>European Neurology</i> , 2005, 53, 22-28.	0.6	17
125	What Do Patients Want from Their Acute Migraine Therapy?. <i>European Neurology</i> , 2005, 53, 3-9.	0.6	132
126	Évaluation de la satisfaction thérapeutique avec Almogran® dans le traitement de 3 crises successives de migraine. <i>Douleurs</i> , 2005, 6, 231-237.	0.0	0



#	ARTICLE	IF	CITATIONS
127	Two replicate randomized, double-blind, placebo-controlled trials of the time to onset of pain relief in the acute treatment of migraine with a fast-disintegrating/rapid-release formulation of sumatriptan tablets. <i>Clinical Therapeutics</i> , 2005, 27, 407-417.	1.1	57
128	Early intervention in migraine with sumatriptan tablets 50 mg versus 100 mg: A pooled analysis of data from six clinical trials. <i>Clinical Therapeutics</i> , 2005, 27, 1785-1794.	1.1	48
129	Rizatriptan in migraine. <i>Expert Review of Neurotherapeutics</i> , 2005, 5, 597-603.	1.4	10
130	Understanding the Needs of Migraine Patients. <i>Drugs</i> , 2006, 66, 1777-8.	4.9	9
131	Strategies to Improve Migraine Treatment Results. <i>Drugs</i> , 2006, 66, 977-81.	4.9	6
132	Osteoporosis Medication Profile Preference: Results from the PREFER-US Study. <i>Journal of Clinical Densitometry</i> , 2006, 9, 250.	0.5	0
133	Migraine preventive therapy: selection of appropriate patients and general principles of management. <i>Expert Review of Neurotherapeutics</i> , 2006, 6, 1147-1157.	1.4	18
134	Pathophysiology of migraine: A role for neuropeptides. <i>Drug Discovery Today Disease Mechanisms</i> , 2006, 3, 327-333.	0.8	6
135	Headache: Recognizing its impact on quality of life and improving management. <i>British Journal of Neuroscience Nursing</i> , 2006, 2, 441-447.	0.1	1
136	Using Patient-Centered Endpoints to Determine the Cost-Effectiveness of Triptans for Acute Migraine Therapy. <i>American Journal of Therapeutics</i> , 2006, 13, 411-417.	0.5	13
137	ACUTE TREATMENT OF MIGRAINE. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2006, 12, 87-105.	0.4	2
138	Patterns of Medical Diagnosis and Treatment of Migraine and Probable Migraine in a Health Plan. <i>Cephalalgia</i> , 2006, 26, 43-49.	1.8	40
139	Subcutaneous Sumatriptan Provides Symptomatic Relief at any Pain Intensity or Time During the Migraine Attack. <i>Cephalalgia</i> , 2006, 26, 113-121.	1.8	37
140	Does Earlier Headache Response Equate to Earlier Return to Functioning in Patients Suffering from Migraine?. <i>Cephalalgia</i> , 2006, 26, 428-435.	1.8	7
141	Efficacy, Speed of Action and Tolerability of Almotriptan in the Acute Treatment of Migraine. <i>Cephalalgia</i> , 2006, 26, 400-408.	1.8	28
142	Preference for Rizatriptan 10-mg Wafer vs. Eletriptan 40-mg Tablet for Acute Treatment of Migraine. <i>Cephalalgia</i> , 2006, 26, 246-256.	1.8	27
143	Oral Sumatriptan for the Acute Treatment of Probable Migraine: First Randomized, Controlled Study. <i>Headache</i> , 2006, 46, 115-124.	1.8	20
144	Zolmitriptan Intranasal: A Review of the Pharmacokinetics and Clinical Efficacy. <i>Headache</i> , 2006, 46, 138-149.	1.8	48

#	ARTICLE	IF	CITATIONS
145	Acetaminophen, Aspirin, and Caffeine in Combination Versus Ibuprofen for Acute Migraine: Results From a Multicenter, Double-Blind, Randomized, Parallel-Group, Single-Dose, Placebo-Controlled Study. <i>Headache</i> , 2006, 46, 444-453.	1.8	100
146	Pain Characteristics of the Acute Migraine Attack. <i>Headache</i> , 2006, 46, 942-953.	1.8	99
147	Behavioral Facilitation of Medical Treatment for Headache—Part I: Review of Headache Treatment Compliance. <i>Headache</i> , 2006, 46, 1387-1394.	1.8	47
148	Cutaneous allodynia and migraine: Another view. <i>Current Pain and Headache Reports</i> , 2006, 10, 231-238.	1.3	6
149	An evaluation of patient preferences for osteoporosis medication attributes: results from the PREFER-US study. <i>Current Medical Research and Opinion</i> , 2006, 22, 949-960.	0.9	33
150	Optimizing migraine therapy: evidence-based and patient-centered care. <i>Expert Review of Neurotherapeutics</i> , 2006, 6, 911-919.	1.4	17
151	Teaching and learning consultation skills for paediatric practice. <i>Archives of Disease in Childhood</i> , 2006, 91, 367-370.	1.0	32
152	Early treatment of migraine attacks with triptans: a strategy to enhance outcomes and patient satisfaction?. <i>Expert Review of Neurotherapeutics</i> , 2006, 6, 1087-1097.	1.4	18
153	Use of almotriptan in triptan-experienced and triptan-naïve patients. <i>Current Medical Research and Opinion</i> , 2007, 23, 2433-2440.	0.9	4
155	Twelve-Month Tolerability and Safety of Sumatriptan-Naproxen Sodium for the Treatment of Acute Migraine. <i>Mayo Clinic Proceedings</i> , 2007, 82, 61-68.	1.4	20
156	Use of the Sustained Pain-Free Plus No Adverse Events Endpoint in Clinical Trials of Triptans in Acute Migraine. <i>CNS Drugs</i> , 2007, 21, 73-82.	2.7	31
157	The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates. <i>Current Medical Research and Opinion</i> , 2007, 23, 3137-3152.	0.9	101
158	Twelve-Month Tolerability and Safety of Sumatriptan-Naproxen Sodium for the Treatment of Acute Migraine. <i>Mayo Clinic Proceedings</i> , 2007, 82, 61-68.	1.4	25
159	Overview of treatment of acute migraine. <i>Drug Development Research</i> , 2007, 68, 441-448.	1.4	1
160	Osteoporosis medication profile preference: results from the PREFER-US study. <i>Health Expectations</i> , 2007, 10, 211-223.	1.1	19
161	Migraine and chronic daily headache management: implications for primary care practitioners. <i>Journal of Clinical Nursing</i> , 2007, 16, 159-167.	1.4	4
162	Patients' Preference for Migraine Preventive Therapy. <i>Headache</i> , 2007, 47, 540-545.	1.8	80
163	Marketed Oral Triptans in the Acute Treatment of Migraine: A Systematic Review on Efficacy and Tolerability. <i>Headache</i> , 2007, 47, 1152-1168.	1.8	58

#	ARTICLE	IF	CITATIONS
164	Predictors of Migraine Headache Recurrence: A Pooled Analysis From the Eletriptan Database. <i>Headache</i> , 2007, 48, 070629211050002-???.	1.8	30
165	Crossover, double-blind clinical trial comparing almotriptan and ergotamine plus caffeine for acute migraine therapy. <i>European Journal of Neurology</i> , 2007, 14, 269-275.	1.7	34
166	Validation of the Eleven-Point Pain Scale in the Measurement of Migraine Headache Pain. <i>Cephalalgia</i> , 2007, 27, 336-342.	1.8	43
167	Almotriptan and zolmitriptan in the acute treatment of migraine. <i>Acta Neurologica Scandinavica</i> , 2007, 115, 34-40.	1.0	34
168	Patient satisfaction with eletriptan in the acute treatment of migraine in primary care. <i>International Journal of Clinical Practice</i> , 2007, 61, 1677-1685.	0.8	11
169	Patient preference in migraine therapy. <i>Journal of Neurology</i> , 2007, 254, 242-249.	1.8	20
170	In-office Discussions of Migraine: Results from the American Migraine Communication Study. <i>Journal of General Internal Medicine</i> , 2008, 23, 1145-1151.	1.3	57
171	Client personality characteristics predict satisfaction with cognitive behavior therapy. <i>Journal of Clinical Psychology</i> , 2008, 64, 40-51.	1.0	8
172	Does the Addition of Dexamethasone to Standard Therapy for Acute Migraine Headache Decrease the Incidence of Recurrent Headache for Patients Treated in the Emergency Department? A Meta-analysis and Systematic Review of the Literature. <i>Academic Emergency Medicine</i> , 2008, 15, 1223-1233.	0.8	60
173	Early Treatment in Migraine: How Strong is the Current Evidence?. <i>Cephalalgia</i> , 2008, 28, 28-35.	1.8	49
174	Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine. <i>Neurology</i> , 2008, 71, 114-121.	1.5	53
175	Parenteral dexamethasone for acute severe migraine headache: meta-analysis of randomised controlled trials for preventing recurrence. <i>BMJ: British Medical Journal</i> , 2008, 336, 1359-1361.	2.4	138
176	Sumatriptan/naproxen sodium combination for the treatment of migraine. <i>Expert Review of Neurotherapeutics</i> , 2008, 8, 1289-1297.	1.4	9
177	Frovatriptan for Acute Treatment of Migraine Associated with Menstruation: Results from an Open-Label Postmarketing Surveillance Study. <i>Journal of Women's Health</i> , 2009, 18, 1265-1273.	1.5	14
178	Early treatment of acute migraine: New evidence of benefits. <i>Cephalalgia</i> , 2009, 29, 15-21.	1.8	9
179	Acute Migraine Treatment With Rizatriptan in Real World Settings – Focusing on Treatment Strategy, Effectiveness, and Behavior. <i>Headache</i> , 2009, 49, S34-42.	1.8	0
180	Consistency of Response to Sumatriptan/Naproxen Sodium in a Placebo-Controlled, Crossover Study. <i>Cephalalgia</i> , 2009, 29, 826-836.	1.8	39
181	Early treatment of acute migraine: new evidence of benefits. <i>Cephalalgia</i> , 2009, 29, 15-21.	1.8	25

#	ARTICLE	IF	CITATIONS
182	Controlled non-invasive transdermal iontophoretic delivery of zolmitriptan hydrochloride in vitro and in vivo. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2009, 72, 304-309.	2.0	37
183	ThÃ©rapeutique de la migraine. , 2009, , 104-131.		0
184	Clinical and Economic Comparison of Frovatriptan Versus other Oral Triptans in the Treatment of Acute Migraine in the Real-World Setting. <i>Clinical Drug Investigation</i> , 2009, 29, 693-702.	1.1	7
185	Acute Treatment of Migraine. <i>Neurologic Clinics</i> , 2009, 27, 417-427.	0.8	33
188	Pharmacological Management of Migraine Headaches. <i>Nurse Practitioner</i> , 2010, 35, 16-22.	0.2	2
190	Rizatriptan for acute migraine headaches in adults. , 2010, , .		2
191	Aspirin with or without an antiemetic for acute migraine headaches in adults. , 2010, , CD008041.		36
193	Zolmitriptan for acute migraine headaches in adults. , 2010, , .		0
194	Treatment of migraine and tension-type headache in Croatia. <i>Journal of Headache and Pain</i> , 2010, 11, 227-234.	2.5	9
195	Are the current IHS guidelines for migraine drug trials being followed?. <i>Journal of Headache and Pain</i> , 2010, 11, 457-468.	2.5	14
196	Safety and tolerability of frovatriptan in the acute treatment of migraine and prevention of menstrual migraine: Results of a new analysis of data from five previously published studies. <i>Gender Medicine</i> , 2010, 7, 88-108.	1.4	22
197	Cutaneous application of menthol 10% solution as an abortive treatment of migraine without aura: a randomised, double-blind, placebo-controlled, crossed-over study. <i>International Journal of Clinical Practice</i> , 2010, 64, 451-456.	0.8	63
198	A New Frontier for Headache. <i>Frontiers in Neurology</i> , 2010, 1, 135.	1.1	4
199	Quantifying the return of headache in triptan-treated migraineurs: An observational study. <i>Cephalalgia</i> , 2010, 30, 838-846.	1.8	19
200	Consistency of response to sumatriptan/naproxen sodium in a placebo-controlled cross-over study. <i>Cephalalgia</i> , 2010, 30, 1277-1279.	1.8	0
201	Migraine recurrence is not associated with depressive or anxiety symptoms. Results of a randomized controlled trial. <i>Cephalalgia</i> , 2010, 30, 690-695.	1.8	5
202	Acute Treatment of Migraine Headaches. <i>Seminars in Neurology</i> , 2010, 30, 145-153.	0.5	5
203	Ibuprofen with or without an antiemetic for acute migraine headaches in adults. , 2010, , CD008039.		26

#	ARTICLE	IF	CITATIONS
204	Sumatriptan plus naproxen for acute migraine headaches in adults. , 2010, 2010, .		2
205	Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults. , 2010, , CD008040.		21
206	Innovative Delivery Systems for Migraine. CNS Drugs, 2010, 24, 929-940.	2.7	46
207	Needle-Free Subcutaneous Sumatriptan. CNS Drugs, 2011, 25, 983-994.	2.7	6
208	The Authors's Reply. CNS Drugs, 2011, 25, 171-173.	2.7	1
209	Needle-free subcutaneous sumatriptan for triptan users requiring a change in migraine therapy: efficacy and impact on patient-rated functionality, satisfaction, and confidence. Current Medical Research and Opinion, 2011, 27, 2185-2191.	0.9	12
210	Evaluation of submicron emulsion as vehicles for rapid-onset intranasal delivery and improvement in brain targeting of zolmitriptan. Drug Delivery, 2011, 18, 578-585.	2.5	13
211	Treatment Satisfaction in Osteoarthritis and Chronic Low Back Pain: The Role of Pain, Physical and Emotional Functioning, Sleep, and Adverse Events. Journal of Pain, 2011, 12, 416-424.	0.7	45
212	Validation of the Peripheral Trigger Point Theory of Migraine Headaches: Single-Surgeon Experience Using Botulinum Toxin and Surgical Decompression. Plastic and Reconstructive Surgery, 2011, 128, 123-131.	0.7	156
214	Total Migraine Freedom, a Potential Primary Endpoint to Assess Acute Treatment in Migraine: Comparison to the Current FDA Requirement Using the Complete Rizatriptan Study Database. Headache, 2011, 51, 356-368.	1.8	17
215	Satisfaction With and Confidence in Needle-Free Subcutaneous Sumatriptan in Patients Currently Treated with Triptans. Headache, 2011, 51, 1202-1211.	1.8	20
216	Characteristics, impact and treatment of 6000 headache attacks: The PAMINA study. European Journal of Pain, 2011, 15, 205-212.	1.4	9
217	Sustained pain freedom and no adverse events as an endpoint in clinical trials of acute migraine treatments: Application to patient-level data from a trial of the CGRP receptor antagonist, telcagepant, and zolmitriptan. Cephalalgia, 2011, 31, 296-300.	1.8	15
219	Prophylactic treatment of migraine by GPs: a qualitative study. British Journal of General Practice, 2012, 62, e268-e274.	0.7	13
220	Oral sumatriptan for acute migraine. The Cochrane Library, 2012, , CD002915.	1.5	2
221	Responsiveness of efficacy endpoints in clinical trials with over the counter analgesics for headache. Cephalalgia, 2012, 32, 953-962.	1.8	5
222	Sumatriptan (rectal route of administration) for acute migraine attacks in adults. The Cochrane Library, 2019, 2019, CD009664.	1.5	41
223	Sumatriptan (intranasal route of administration) for acute migraine attacks in adults. The Cochrane Library, 2019, 2019, CD009663.	1.5	22

#	ARTICLE	IF	CITATIONS
224	Sumatriptan (subcutaneous route of administration) for acute migraine attacks in adults. The Cochrane Library, 2019, 2019, CD009665.	1.5	22
225	Diclofenac with or without an antiemetic for acute migraine headaches in adults. , 2012, , CD008783.		15
226	Therapeutic applications for subcutaneous triptans in the acute treatment of migraine. Current Medical Research and Opinion, 2012, 28, 1231-1238.	0.9	6
227	Sumatriptan (oral route of administration) for acute migraine attacks in adults. The Cochrane Library, 2019, 2019, CD008615.	1.5	46
228	Comparison of Expected Outcomes between Patients and Neurologists Using Kano's Methodology in Symptomatic Migraine Treatment. Patient, 2012, 5, 147-162.	1.1	9
229	Taking the Negative View of Current Migraine Treatments. CNS Drugs, 2012, 26, 375-382.	2.7	63
230	Twelve-Month Tolerability and Efficacy Study of NP101, the Sumatriptan Iontophoretic Transdermal System. Headache, 2012, 52, 612-624.	1.8	29
231	The Development of a Survey to Measure Completeness of Response to Migraine Therapy. Headache, 2012, 52, 550-572.	1.8	9
232	Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults. The Cochrane Library, 2019, 2019, CD008040.	1.5	58
233	Naproxen with or without an antiemetic for acute migraine headaches in adults. The Cochrane Library, 2013, , CD009455.	1.5	28
234	Health-care utilization for primary headache disorders in China: a population-based door-to-door survey. Journal of Headache and Pain, 2013, 14, 47.	2.5	43
235	Survey of Migraine Sufferers with Dogs to Evaluate for Canine Migraine-Alerting Behaviors. Journal of Alternative and Complementary Medicine, 2013, 19, 501-508.	2.1	11
236	An Open-Label Trial of a Sumatriptan Auto-Injector for Migraine in Patients Currently Treated With Subcutaneous Sumatriptan. Headache, 2013, 53, 118-125.	1.8	6
237	Sumatriptan: a review of its pharmacokinetics, pharmacodynamics and efficacy in the acute treatment of migraine. Expert Opinion on Drug Metabolism and Toxicology, 2013, 9, 91-103.	1.5	27
238	What works for whom? Determining the efficacy and harm of treatments for pain. Pain, 2013, 154, S77-S86.	2.0	39
239	Intranasal Zolmitriptan for the Treatment of Acute Migraine. Headache, 2013, 53, 62-71.	1.8	22
240	Diclofenac with or without an antiemetic for acute migraine headaches in adults. The Cochrane Library, 2019, 2019, CD008783.	1.5	28
241	Efficacy endpoints in migraine clinical trials: the importance of assessing freedom from pain. Current Medical Research and Opinion, 2013, 29, 861-867.	0.9	11

#	ARTICLE	IF	CITATIONS
242	Sumatriptan plus naproxen for acute migraine attacks in adults. , 2013, , CD008541.		14
243	Client Perceptions of Therapy Component Helpfulness in Group Cognitive Behavioral Therapy for Anxiety Disorders. <i>Journal of Clinical Psychology</i> , 2013, 69, 229-239.	1.0	18
244	Ibuprofen with or without an antiemetic for acute migraine headaches in adults. <i>The Cochrane Library</i> , 2019, 2019, CD008039.	1.5	81
245	Targeted Review: Medications for Acute Migraine Treatment. <i>Canadian Journal of Neurological Sciences</i> , 2013, 40, S10-S32.	0.3	2
246	Targeted Review: Medications for Acute Migraine Treatment. <i>Canadian Journal of Neurological Sciences</i> , 2013, 40, S10-S32.	0.3	3
247	Aspirin with or without an antiemetic for acute migraine headaches in adults. <i>The Cochrane Library</i> , 2019, 2019, CD008041.	1.5	44
248	What Do Patients Consider to Be the Most Important Outcomes for Effectiveness Studies on Migraine Treatment? Results of a Delphi Study. <i>PLoS ONE</i> , 2014, 9, e98933.	1.1	48
249	The Efficacy of Transdermal Sumatriptan Is Too Low for General Use – a Response. <i>Headache</i> , 2014, 54, 172-174.	1.8	1
250	Consistency of eletriptan in treating migraine: Results of a randomized, within-patient multiple-dose study. <i>Cephalalgia</i> , 2014, 34, 126-135.	1.8	10
251	Potential effect and mechanism of action of topical chamomile ( <i>Matricaria chamomilla</i> L.) oil on migraine headache: A medical hypothesis. <i>Medical Hypotheses</i> , 2014, 83, 566-569.	0.8	45
252	Sumatriptan (all routes of administration) for acute migraine attacks in adults - overview of Cochrane reviews. <i>The Cochrane Library</i> , 2019, 2019, CD009108.	1.5	64
253	Zolmitriptan for acute migraine attacks in adults. <i>The Cochrane Library</i> , 2014, , CD008616.	1.5	22
254	Acute Migraine Treatment. <i>Headache</i> , 2015, 55, 1-2.	1.8	7
255	What efficacy measures are clinically relevant and should be used in Cochrane Reviews of acute migraine trials? A viewpoint. <i>Cephalalgia</i> , 2015, 35, 457-459.	1.8	3
256	Recommendations for the treatment of migraine attacks - a Brazilian consensus. <i>Arquivos De Neuro-Psiquiatria</i> , 2016, 74, 262-271.	0.3	13
258	Sumatriptan plus naproxen for the treatment of acute migraine attacks in adults. <i>The Cochrane Library</i> , 2016, 4, CD008541.	1.5	29
259	Migraine factors as reported by smartphone users. , 2016, 2016, 271-274.		4
260	A Randomized Trial Comparing the Pharmacokinetics, Safety, and Tolerability of DFN-02, an Intranasal Sumatriptan Spray Containing a Permeation Enhancer, With Intranasal and Subcutaneous Sumatriptan in Healthy Adults. <i>Headache</i> , 2016, 56, 1455-1465.	1.8	24



#	ARTICLE	IF	CITATIONS
263	Use of melatonin versus valproic acid in prophylaxis of migraine patients: A double-blind randomized clinical trial. <i>Restorative Neurology and Neuroscience</i> , 2017, 35, 385-393.	0.4	38
265	Migraine headache trigger site prevalence analysis of 2590 sites in 1010 patients. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2017, 70, 152-158.	0.5	27
266	100% Response Rate to Galcanezumab in Patients With Episodic Migraine: A Post Hoc Analysis of the Results From Phase 3, Randomized, Double-blind, Placebo-controlled EVOLVE <sup>1</sup> and EVOLVE <sup>2</sup> Studies. <i>Headache</i> , 2018, 58, 1347-1357.	1.8	29
267	Evaluation of the effect of topical chamomile ( <i>Matricaria chamomilla</i> L.) oleogel as pain relief in migraine without aura: a randomized, double-blind, placebo-controlled, crossover study. <i>Neurological Sciences</i> , 2018, 39, 1345-1353.	0.9	38
268	Migraine Surgery. , 2018, , .		3
269	What Is Migraine?. , 2018, , 7-30.		1
270	DFN <sup>02</sup> (Sumatriptan 10 mg With a Permeation Enhancer) Nasal Spray vs Placebo in the Acute Treatment of Migraine: A Double-blind, Placebo-controlled Study. <i>Headache</i> , 2018, 58, 676-687.	1.8	31
271	Vancouver Declaration on Global Headache Patient Advocacy 2018. <i>Cephalalgia</i> , 2018, 38, 1899-1909.	1.8	24
272	Unmet Acute Treatment Needs From the 2017 Migraine in America Symptoms and Treatment Study. <i>Headache</i> , 2019, 59, 1310-1323.	1.8	54
273	Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2019, 394, 737-745.	6.3	236
274	Acute Treatment of Migraine. <i>Neurologic Clinics</i> , 2019, 37, 727-742.	0.8	17
275	Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. <i>Brain</i> , 2019, 142, 1894-1904.	3.7	191
276	The Public's Perception of Interventions for Migraine Headache Disorders: A Crowdsourcing Population-Based Study. <i>Aesthetic Surgery Journal Open Forum</i> , 2019, 1, ojz007.	0.5	6
277	The discovery and development of inhaled therapeutics for migraine. <i>Expert Opinion on Drug Discovery</i> , 2019, 14, 591-599.	2.5	4
278	Generational differences in complementary medicine use in young Australian women: Repeated cross-sectional dataset analysis from the Australian longitudinal study on women's health. <i>Complementary Therapies in Medicine</i> , 2019, 43, 66-72.	1.3	7
279	Acute Migraine: Can the New Drugs Clinically Outpace?. <i>SN Comprehensive Clinical Medicine</i> , 2020, 2, 1132-1138.	0.3	17
280	Remote Electrical Neuromodulation for the Acute Treatment of Migraine in Patients with Chronic Migraine: An Open-Label Pilot Study. <i>Pain and Therapy</i> , 2020, 9, 531-543.	1.5	21
281	Real-world Experience with Remote Electrical Neuromodulation in the Acute Treatment of Migraine. <i>Pain Medicine</i> , 2020, 21, 3522-3529.	0.9	10



#	ARTICLE	IF	CITATIONS
282	A global real-world assessment of the impact on health-related quality of life and work productivity of migraine in patients with insufficient versus good response to triptan medication. <i>Journal of Headache and Pain</i> , 2020, 21, 41.	2.5	32
283	A Real-World Analysis of Patient Characteristics, Treatment Patterns, and Level of Impairment in Patients With Migraine Who are Insufficient Responders vs Responders to Acute Treatment. <i>Headache</i> , 2020, 60, 1325-1339.	1.8	14
284	Unmet Needs in Japanese Patients Who Report Insufficient Efficacy with Triptans for Acute Treatment of Migraine: Retrospective Analysis of Real-World Data. <i>Pain and Therapy</i> , 2021, 10, 415-432.	1.5	4
285	Randomized, controlled trial of lasmiditan over four migraine attacks: Findings from the CENTURION study. <i>Cephalalgia</i> , 2021, 41, 294-304.	1.8	34
286	Nasal Delivery of Acute Medications for Migraine: The Upper Versus Lower Nasal Space. <i>Journal of Clinical Medicine</i> , 2021, 10, 2468.	1.0	19
287	Patients and general practitioners assessment of the main outcomes employed in the acute and preventive treatment of migraine: a cross sectional study. <i>BMC Neurology</i> , 2021, 21, 279.	0.8	2
288	Reduction in migraine pain intensity in patients treated with erenumab: A post hoc analysis of two pivotal randomized studies. <i>Cephalalgia</i> , 2021, 41, 033310242110289.	1.8	3
289	A close association of freedom from pain, migraine-related functional disability, and other outcomes: results of a post hoc analysis of randomized lasmiditan studies SAMURAI and SPARTAN. <i>Journal of Headache and Pain</i> , 2021, 22, 101.	2.5	3
290	Patient Preferences and Values in Decision Making for Migraines: A Systematic Literature Review. <i>Pain Research and Management</i> , 2021, 2021, 1-9.	0.7	7
291	Remote Electrical Neuromodulation for the Acute Treatment of Episodic and Chronic Migraine. <i>Touch Reviews in Neurology</i> , 2021, 17, 6.	0.1	0
292	Ditans vs Gepants: A Systematic Review and Indirect Network Meta-Analysis for Comparative Analysis of Efficacy and Safety. <i>Neurology India</i> , 2021, 69, 43.	0.2	5
293	Eletriptan for acute migraine headaches in adults. , 2010, 2010, .		2
294	Treatment of Mild Headache in Disabled Migraine Sufferers: Results of the Spectrum Study. <i>Headache</i> , 2000, 40, 792-797.	1.8	160
295	Remote electrical neuromodulation for acute treatment of migraine in adolescents. <i>Headache</i> , 2021, 61, 310-317.	1.8	34
296	Assessing the Impact of Migraine. <i>Current Medical Research and Opinion</i> , 2001, 17, 298-309.	0.9	74
298	Guidelines for Prescribing Prophylactic Medications for Migraine: A Survey Among Headache Specialist Physicians in Different Countries. <i>Headache Care</i> , 2004, 1, 267-272.	0.2	11
299	Headache-related disability in the management of migraine. <i>Neurology</i> , 2001, 56, S1-3.	1.5	23
300	Migraine-related disability. <i>Neurology</i> , 2001, 56, S13-9.	1.5	41

#	ARTICLE	IF	CITATIONS
301	Potential of the Migraine Disability Assessment (MIDAS) Questionnaire as a public health initiative and in clinical practice. <i>Neurology</i> , 2001, 56, S29-34.	1.5	35
302	Diagnostic lessons from the Spectrum Study. <i>Neurology</i> , 2002, 58, S27-31.	1.5	106
303	Clinical applications of new therapeutic deliveries in migraine. <i>Neurology</i> , 2003, 61, S31-4.	1.5	25
304	Migraine throughout the life cycle. <i>Neurology</i> , 2004, 62, S2-8.	1.5	41
305	Acupuncture or Low Frequency Infrared Treatment for Low Back Pain in Chinese Patients: A Discrete Choice Experiment. <i>PLoS ONE</i> , 2015, 10, e0126912.	1.1	14
307	Rizatriptan in the treatment of migraine. <i>Neuropsychiatric Disease and Treatment</i> , 2006, 2, 247-259.	1.0	24
308	Safety and efficacy of remote electrical neuromodulation for the acute treatment of chronic migraine: an open-label study. <i>Pain Reports</i> , 2021, 6, e966.	1.4	12
311	Acute Treatment Options for the Pregnant Headache Patient. , 2009, , 71-100.		0
312	Appendices: Patient Educational Materials. , 2009, , 381-383.		0
316	Comparison of Expected Outcomes between Patients and Neurologists Using Kano's Methodology in Symptomatic Migraine Treatment. <i>Patient</i> , 2012, 5, 147-162.	1.1	7
320	Acute Treatment of Episodic Migraine. , 2014, , 145-159.		0
321	Thérapeutique de la migraine. , 2015, , 127-159.		0
322	The Migraine Team. , 2017, , 61-69.		0
323	Acute Treatment of Migraine. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2018, 24, 1032-1051.	0.4	9
324	A Human Factors Study Exploring the Experience of Participants Using VEGA, a Smartphone Migraine Management Application. , 0, , .		0
325	Trainee Headache Education and Management Enhancement (THEME) Study. <i>Canadian Journal of Neurological Sciences</i> , 2023, 50, 458-461.	0.3	2
326	Low adherence to the guideline for the acute treatment of migraine. <i>Scientific Reports</i> , 2022, 12, 8487.	1.6	12
327	Rapid Onset and Sustained Efficacy of Lasmiditan Among Japanese Patients with Migraine: Prespecified Analyses of a Randomized Controlled Trial. <i>Neurology and Therapy</i> , 2022, 11, 1721-1734.	1.4	3

#	ARTICLE	IF	CITATIONS
328	Variability in recurrence rates with acute treatments for migraine: why recurrence is not an appropriate outcome measure. <i>Journal of Headache and Pain</i> , 2022, 23, .	2.5	2
329	The Strong Black Woman Archetype and Therapeutic Outcomes: Examining Relationships Among Women with Childhood Sexual Abuse Histories. <i>Journal of Racial and Ethnic Health Disparities</i> , 0, , .	1.8	1
330	In Vivo Evaluation of Almotriptan malate Formulation through Intranasal Route for the Treatment of Migraine: Systematic Development and Pharmacokinetic Assessment. <i>AAPS PharmSciTech</i> , 2023, 24, .	1.5	5
331	Time for humanity from doctors towards patients. <i>Postgraduate Medical Journal</i> , 2003, 79, 667-668.	0.9	1
332	Efficacy of rimegepant for the acute treatment of migraine based on triptan treatment experience: Pooled results from three phase 3 randomized clinical trials. <i>Cephalalgia</i> , 2023, 43, 033310242211416.	1.8	7